Principal Investigator

NCCN Member Institution

Title

Publication

Patrick Creaven, MD, PhD

Roswell Park Cancer Institute

A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer

Cancer Chemotherapy and Pharmacology

Manuel Hidalgo, MD, PhD

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Assessment of Celecoxib Pharmacodynamics in Pancreatic Cancer

Molecular Cancer Therapeutics

Milind Javle, MD

Roswell Park Cancer Institute

Celecoxib and Mucosal Protection: Translation from an Animal Model to a Phase I Clinical Trial of Celecoxib, Irinotecan, and 5-Fluorouracil

Clinical Cancer Research

Brian Rini, MD

UCSF Helen Diller Family Comprehensive Cancer Center

Maximal COX-2 Immunostaining Predicts Clinical Response to Celecoxib and Interferon Alpha Therapy in Metastatic Renal Cell Carcinoma

Cancer

M. Wasif Saif, MD, MBBS

University of Alabama at Birmingham Comprehensive Cancer Center

A phase I study of bi-weekly administration of 24-h gemcitabine followed by 24-h irinotecan in patients with solid tumors

Cancer Chemotherapy and Pharmacology

Manisha Shah, MD

Arthur G. James Cancer Hospital & Richard J. Solove Research Institute at The Ohio State University

Phase II Study of Celecoxib in Metastatic Differentiated Thyroid Carcinoma

The Journal of Clinical Endocrinology & Metabolism

Manisha Shah, MD

Arthur G. James Cancer Hospital & Richard J. Solove Research Institute at The Ohio State University

High-dose celecoxib does not improve survival of patients with differentiated thyroid cancer

Nature Clinical Practice Endocrinology & Metabolism

Przemyslaw Twardowski, MD

City of Hope

Biologic Markers of Angiogenesis: Circulating Endothelial Cells in Patients with Advanced Malignancies Treated on Phase I Protocol with Metronomic Chemotherapy and Celecoxib

Cancer Investigation